Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases
Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases
The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
1430-1438
Shuttleworth, Stephen J.
303af312-bed4-49b5-8d79-e80d7b6d96da
Bailey, Sarah G.
3907c846-1c65-490a-81f1-653fea9ff7f0
Townsend, Paul A.
a2680443-664e-46d0-b4dd-97456ba810db
November 2010
Shuttleworth, Stephen J.
303af312-bed4-49b5-8d79-e80d7b6d96da
Bailey, Sarah G.
3907c846-1c65-490a-81f1-653fea9ff7f0
Townsend, Paul A.
a2680443-664e-46d0-b4dd-97456ba810db
Shuttleworth, Stephen J., Bailey, Sarah G. and Townsend, Paul A.
(2010)
Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases.
Current Drug Targets, 11 (11), .
(doi:10.2174/1389210205839724501).
(PMID:20583972)
Abstract
The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
This record has no associated files available for download.
More information
Published date: November 2010
Identifiers
Local EPrints ID: 161299
URI: http://eprints.soton.ac.uk/id/eprint/161299
ISSN: 1389-4501
PURE UUID: 9f38c63a-14e5-41d3-83ee-a934d8252731
Catalogue record
Date deposited: 27 Jul 2010 14:32
Last modified: 14 Mar 2024 01:59
Export record
Altmetrics
Contributors
Author:
Stephen J. Shuttleworth
Author:
Sarah G. Bailey
Author:
Paul A. Townsend
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics